These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 15531766)

  • 41. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.
    Valgimigli M; Campo G; Arcozzi C; Malagutti P; Carletti R; Ferrari F; Barbieri D; Parrinello G; Percoco G; Ferrari R
    J Am Coll Cardiol; 2007 Jul; 50(2):138-45. PubMed ID: 17616297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of abciximab on prognosis in diabetic patients undergoing primary percutaneous coronary intervention.
    Perkan A; Vitrella G; Barbati G; De Monte A; D'Agata B; Merlo M; Giannini F; Della Grazia E; Rakar S; Salvi A; Igidbashian D; Morgera T; Zalukar W; Sinagra G
    J Cardiovasc Med (Hagerstown); 2013 Feb; 14(2):127-35. PubMed ID: 22343257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
    Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
    Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.
    Ndrepepa G; Berger PB; Mehilli J; Seyfarth M; Neumann FJ; Schömig A; Kastrati A
    J Am Coll Cardiol; 2008 Feb; 51(7):690-7. PubMed ID: 18279731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.
    Schulz S; Mehilli J; Ndrepepa G; Dotzer F; Dommasch M; Kufner S; Birkmeier KA; Tiroch K; Byrne RA; Schömig A; Kastrati A
    Clin Res Cardiol; 2011 Aug; 100(8):691-9. PubMed ID: 21384174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
    Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
    Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.
    Rakowski T; Siudak Z; Dziewierz A; Birkemeyer R; Legutko J; Mielecki W; Depukat R; Janzon M; Stefaniak J; Zmudka K; Dubiel JS; Partyka L; Dudek D
    Am Heart J; 2009 Oct; 158(4):569-75. PubMed ID: 19781416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
    JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade: the triad revisited.
    Tang WH; Lincoff AM
    Circulation; 2004 Dec; 110(24):3618-20. PubMed ID: 15596556
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.
    Neumann FJ; Kastrati A; Schmitt C; Blasini R; Hadamitzky M; Mehilli J; Gawaz M; Schleef M; Seyfarth M; Dirschinger J; Schömig A
    J Am Coll Cardiol; 2000 Mar; 35(4):915-21. PubMed ID: 10732888
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty.
    Fuchs S; Kornowski R; Mehran R; Gruberg L; Satler LF; Pichard AD; Kent KM; Stone GW; Leon MB
    J Invasive Cardiol; 2000 Oct; 12(10):497-501. PubMed ID: 11022207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.
    Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL
    Catheter Cardiovasc Interv; 2010 May; 75(6):895-902. PubMed ID: 20088008
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial.
    Cho L; Marso SP; Bhatt DL; Topol EJ
    J Womens Health Gend Based Med; 2000 Sep; 9(7):741-6. PubMed ID: 11025866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
    Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction.
    Exaire JE; Fathi RB; Brener SJ; Karha J; Ellis SG; Bhatt DL
    Arch Cardiol Mex; 2006; 76(4):376-82. PubMed ID: 17315613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting.
    De Luca L; De Persio G; Minati M; Iacoboni C; Fedele F
    Am Heart J; 2005 Jun; 149(6):1135. PubMed ID: 15976799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.